Analysis Of The Efficacy Of Fruquintinib In The Treatment Of Advanced Solid Tumors With Failed Standard Regimen

Background and Objectives:Fruquintinib is a small molecular tyrosine kinase inhibi-tor developed independently in China.It has high selectivity to VEGFR-1,VEGFR-2and VEGFR-3.In clinical trials involving a series of patients with solid tumor types,the antitumor activity of fruquintinib has been demonstrated,including colorectal cancer,non-small cell lung cancer and so on,and has been approved for the third-line treatment of advanced colorectal cancer.The purpose of this study was to observe the efficacy and side effects of fruquintinib in patients with different advanced solid tumors who had failed to receive second-line or more treatment in the past..Methods:To collect the clinical general information and follow-up data of patients with colorectal cancer and non-small cell lung cancer treated by oral fruquintinib in our hos-pital from March 2015 to Feb 2019.The standard dose of fruquintinib was taken orally5mg every day.Take medicine for 3 weeks,stop taking medicine for 1 week,supple-mented by the best support treatment,continuous use of drugs untilthe disease progresses,intolerable adverse events,death or the patient refuses to continue treat-ment.During the period,the changes of target lesions were observed by con-trast-enhanced CT every 8 weeks.The curative effect was evaluated according to the evaluation standard of solid tumor curative effect,counte the cases of CR,PR,SD and PD respectively,and the objective remission rate and disease control rate were calcu-lated.The data between groups were compared according to?~2test.Non-parametric test was used to compare the difference of progression-free survival time in patients with different clinical features.Kplan-Meier was used to analyze the survival situation.It was considered that there was significant difference between the two groups(P<0.05).Results:The clinical information of 50 patients with advanced solid tumor was collected.As of the end of follow-up,46 patients could evaluate the curative effect.The number of patients who obtained CR,PR,SD and PD were 0(0.0%),6(13.0%),19(41.3%)and21(43.7%),ORR and DCR were 13.0%and 54.3%,respectively.In the colorectal can-cer group,there were 0 cases of complete remission,1 case of partial remission,10 cas-es of stable disease,8 cases of disease progress.In patients with non-small cell lung cancer.,there were 0 cases of complete remission and 2 cases of partial remission,the disease was stable in 7 cases and advanced in 9 cases.The ORR of colorectal cancer was 5.3%,DCR was 57.9%,mPFS was 4.1 months,mOS was 12.0 months,which was similar to that of FRESCO study.The mPFS of patients with non-small cell lung cancer was 1.8 months,and the rest of the tumors could not be further evaluated for survival.The common adverse reactions of fruquintinib in the treatment of advanced solid tumor include hypertension,albuminuria,hand and foot syndrome,hoarseness and diarrhea and abdominal pain,and the degree of tolerance is good.Conclusion:Fruquintinib has a good disease control rate for advanced solid tumors in which the standard regimen fails.The survival time has been improved in colorectal cancer,and the adverse reactions can be controlled as a whole,but the number of cases is small,and further clinical observation is needed.